Ortataxel

Ortataxel

 

A third generation taxane classified as a New Chemical Entity (NCE)

 

Status

Phase 2 studies in taxane-refractory solid tumors have indicated a substantial level of antitumor activity

Properties

Safety data from Phase 1 and Phase 2 studies show a similar toxicity/tolerance profile to paclitaxel

Target Indications
  • Solid tumors
  • Has potential to be active in tumors resistant to paclitaxel and docetaxel
Route of Administration
  • Intravenous
  • Orally bioavailable
Mode of Action
  • Microtubule stabilization leading to mitotic arrest
  • Overcomes taxane resistence based on PgP-170 overexpression
Status
  • Phase 2 trials